Deutsche Bank AG Sells 80,170 Shares of Haemonetics Corporation $HAE

Deutsche Bank AG lessened its stake in shares of Haemonetics Corporation (NYSE:HAE - Free Report) by 16.7% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 399,415 shares of the medical instruments supplier's stock after selling 80,170 shares during the period. Deutsche Bank AG owned 0.80% of Haemonetics worth $25,383,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Voya Investment Management LLC grew its holdings in Haemonetics by 820.5% during the 4th quarter. Voya Investment Management LLC now owns 316,952 shares of the medical instruments supplier's stock valued at $24,748,000 after buying an additional 282,521 shares in the last quarter. Stifel Financial Corp lifted its position in shares of Haemonetics by 7.3% in the fourth quarter. Stifel Financial Corp now owns 14,776 shares of the medical instruments supplier's stock worth $1,154,000 after buying an additional 1,006 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in shares of Haemonetics by 9.6% in the fourth quarter. Envestnet Asset Management Inc. now owns 48,068 shares of the medical instruments supplier's stock valued at $3,753,000 after purchasing an additional 4,217 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Haemonetics by 434.8% in the fourth quarter. The Manufacturers Life Insurance Company now owns 314,067 shares of the medical instruments supplier's stock valued at $24,522,000 after purchasing an additional 255,338 shares in the last quarter. Finally, Hood River Capital Management LLC grew its holdings in shares of Haemonetics by 6.8% in the fourth quarter. Hood River Capital Management LLC now owns 214,290 shares of the medical instruments supplier's stock valued at $16,732,000 after purchasing an additional 13,710 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

Haemonetics Trading Down 0.0%

Shares of HAE traded down $0.01 during trading hours on Monday, reaching $53.74. 179,879 shares of the company traded hands, compared to its average volume of 798,037. The firm has a market cap of $2.59 billion, a price-to-earnings ratio of 16.45, a PEG ratio of 0.99 and a beta of 0.40. Haemonetics Corporation has a 12-month low of $50.68 and a 12-month high of $94.99. The company has a current ratio of 1.72, a quick ratio of 1.04 and a debt-to-equity ratio of 1.04. The stock's fifty day moving average price is $71.19 and its 200 day moving average price is $66.77.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.09. The firm had revenue of $321.39 million during the quarter, compared to the consensus estimate of $305.12 million. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%. The firm's quarterly revenue was down 4.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.02 earnings per share. Sell-side analysts forecast that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Wall Street Zen lowered shares of Haemonetics from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th. Mizuho cut their target price on shares of Haemonetics from $90.00 to $70.00 and set an "outperform" rating for the company in a report on Friday, August 8th. Barrington Research cut their target price on shares of Haemonetics from $95.00 to $86.00 and set an "outperform" rating for the company in a report on Friday, August 8th. Needham & Company LLC reaffirmed a "buy" rating and set a $68.00 price objective (down from $84.00) on shares of Haemonetics in a research note on Thursday, August 7th. Finally, JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $62.00 price objective (down from $85.00) on shares of Haemonetics in a research note on Friday, August 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $85.18.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.